Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(3.47)
# 834
Out of 4,650 analysts
439
Total ratings
45.91%
Success rate
5.15%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Reiterates: Buy | $70 | $45.90 | +52.51% | 10 | Oct 28, 2024 | |
| MRNS Marinus Pharmaceuticals | Downgrades: Neutral | n/a | $0.29 | - | 18 | Oct 25, 2024 | |
| ALKS Alkermes | Reiterates: Neutral | $37 | $26.44 | +39.94% | 22 | Oct 25, 2024 | |
| DARE Daré Bioscience | Reiterates: Buy | $12 | $3.96 | +203.03% | 14 | Oct 24, 2024 | |
| SAGE Sage Therapeutics | Reiterates: Neutral | $25 | $8.48 | +194.81% | 19 | Oct 9, 2024 | |
| EOLS Evolus | Reiterates: Buy | $27 | $16.69 | +61.77% | 21 | Oct 3, 2024 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $53 | $41.78 | +26.85% | 1 | Oct 1, 2024 | |
| NMRA Neumora Therapeutics | Initiates: Buy | $30 | $11.73 | +155.75% | 1 | Oct 1, 2024 | |
| AEON AEON Biopharma | Reiterates: Buy | $5 | $0.98 | +410.20% | 8 | Oct 1, 2024 | |
| IMVT Immunovant | Reiterates: Buy | $51 | $29.88 | +70.68% | 18 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $5.68 | +146.48% | 13 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $59 | $50.95 | +15.80% | 10 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $11.58 | +55.44% | 15 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $4.20 | +495.24% | 20 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.74 | +1,514.21% | 20 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $8.65 | +73.41% | 13 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $50 | $48.43 | +3.24% | 21 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $22.74 | +18.73% | 12 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $120 | $71.03 | +68.94% | 19 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $4.43 | +306.32% | 10 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $8 | $3.92 | +104.08% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.74 | +422.65% | 13 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $69 | $56.26 | +22.64% | 21 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $5 | $2.54 | +96.50% | 12 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $83 | $27.41 | +202.81% | 22 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $504 → $533 | $552.88 | -3.60% | 30 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $5.91 | +86.13% | 18 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.57 | +536.94% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $10 | $17.14 | -41.66% | 7 | Dec 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $232.40 | -21.69% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $5.74 | +226.66% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $23.50 | -23.40% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $18.43 | -56.59% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $17.18 | +202.68% | 2 | Jun 11, 2019 |
Disc Medicine
Oct 28, 2024
Reiterates: Buy
Price Target: $70
Current: $45.90
Upside: +52.51%
Marinus Pharmaceuticals
Oct 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.29
Upside: -
Alkermes
Oct 25, 2024
Reiterates: Neutral
Price Target: $37
Current: $26.44
Upside: +39.94%
Daré Bioscience
Oct 24, 2024
Reiterates: Buy
Price Target: $12
Current: $3.96
Upside: +203.03%
Sage Therapeutics
Oct 9, 2024
Reiterates: Neutral
Price Target: $25
Current: $8.48
Upside: +194.81%
Evolus
Oct 3, 2024
Reiterates: Buy
Price Target: $27
Current: $16.69
Upside: +61.77%
Xenon Pharmaceuticals
Oct 1, 2024
Initiates: Buy
Price Target: $53
Current: $41.78
Upside: +26.85%
Neumora Therapeutics
Oct 1, 2024
Initiates: Buy
Price Target: $30
Current: $11.73
Upside: +155.75%
AEON Biopharma
Oct 1, 2024
Reiterates: Buy
Price Target: $5
Current: $0.98
Upside: +410.20%
Immunovant
Sep 30, 2024
Reiterates: Buy
Price Target: $51
Current: $29.88
Upside: +70.68%
Sep 27, 2024
Reiterates: Buy
Price Target: $14
Current: $5.68
Upside: +146.48%
Sep 24, 2024
Reiterates: Buy
Price Target: $59
Current: $50.95
Upside: +15.80%
Sep 19, 2024
Reiterates: Buy
Price Target: $18
Current: $11.58
Upside: +55.44%
Sep 17, 2024
Reiterates: Buy
Price Target: $25
Current: $4.20
Upside: +495.24%
Sep 16, 2024
Reiterates: Buy
Price Target: $12
Current: $0.74
Upside: +1,514.21%
Sep 16, 2024
Reiterates: Buy
Price Target: $15
Current: $8.65
Upside: +73.41%
Sep 12, 2024
Maintains: Buy
Price Target: $40 → $50
Current: $48.43
Upside: +3.24%
Sep 10, 2024
Reiterates: Buy
Price Target: $27
Current: $22.74
Upside: +18.73%
Sep 10, 2024
Reiterates: Buy
Price Target: $120
Current: $71.03
Upside: +68.94%
Aug 19, 2024
Reiterates: Buy
Price Target: $18
Current: $4.43
Upside: +306.32%
Aug 15, 2024
Maintains: Buy
Price Target: $11 → $8
Current: $3.92
Upside: +104.08%
Aug 15, 2024
Reiterates: Buy
Price Target: $30
Current: $5.74
Upside: +422.65%
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $69
Current: $56.26
Upside: +22.64%
Aug 7, 2024
Maintains: Neutral
Price Target: $7 → $5
Current: $2.54
Upside: +96.50%
Aug 2, 2024
Maintains: Buy
Price Target: $92 → $83
Current: $27.41
Upside: +202.81%
Jul 26, 2024
Maintains: Buy
Price Target: $504 → $533
Current: $552.88
Upside: -3.60%
May 13, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $5.91
Upside: +86.13%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.57
Upside: +536.94%
Dec 9, 2021
Maintains: Neutral
Price Target: $23 → $10
Current: $17.14
Upside: -41.66%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $232.40
Upside: -21.69%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $5.74
Upside: +226.66%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $23.50
Upside: -23.40%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $18.43
Upside: -56.59%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $17.18
Upside: +202.68%